Dr. Yi Feng, MD

Dr. Feng practices at Tennessee Cancer Specialists in Powell, Tennessee.

Dr. Feng's NPI, 1639179229, was assigned on July 26, 2005. Dr. Feng holds Tennessee license MD0000038385.

Dr. Feng's primary practice is Tennessee Cancer Specialists, at 7650 Dannaher Dr, Powell, TN 37849 in Knox County. The practice phone is (865) 637-9330.

Dr. Feng's primary practice is Tennessee Cancer Specialists in Powell, Tennessee. Dr. Feng is also affiliated with Tennova North Knoxville Medical Center. The medical group on file is Tennessee Cancer Specialists. Dmand AI also links Dr. Feng to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feng practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Feng's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Feng's licenses on file in 2 states: Tennessee and Kentucky.

CMS data shows 293,264 Medicare services from Dr. Feng across 76 procedure codes in 2024, for 1,028 Medicare patients. Medicare paid $4,705,849 for them. Every service was in an office.

CMS counts 1,028 Medicare patients who saw Dr. Feng in 2024. The largest group is 65 to 74, with 433 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feng's median patient age at 71, with 59% women.

In 2024, Dr. Feng wrote 2,136 Medicare Part D claims for 399 patients. 72% of them were for generic drugs. CMS names the drug for 1,868 of them, across 49 drugs with 11 or more claims each, at $4,903,298 in total drug cost. In 2023, CMS named 1,961 claims across 54 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Feng for performance year 2024, reported individually. Dr. Feng accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Feng, published from 2012 to 2024. 2023 was the busiest year, with 2. The most frequent topics are Bone Marrow. Dr. Feng has published most often in Int J Hematol. Dr. Feng's most frequent co-author is Jing Jin, MD.

CMS Open Payments shows 2,158 general payments to Dr. Feng from 88 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. AstraZeneca Pharmaceuticals LP paid the most, $10,485.